Inicio/Acciones/OMER

OMER

USD

Omeros Corporation Common Stock

$6.730-0.330 (-4.674%)

Precio en Tiempo Real

Healthcare

Biotecnología

Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$7.060

Máximo

$7.240

Mínimo

$6.710

Volumen

1.29M

Fundamentos de la Empresa

Capitalización de Mercado

458.0M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

3.30M

Bolsa

NGM

Moneda

USD

Rango de 52 Semanas

Mínimo $2.95Actual $6.730Máximo $13.6

Noticias Relacionadas

15 oct 2025 · 12:34

Reuters

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and kidney disorders, they said on Wednesday.

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

15 oct 2025 · 12:30

GlobeNewswire

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in upfront and near-term